Method of prevention of tuberculosis of the deer |
|
IPC classes for russian patent Method of prevention of tuberculosis of the deer (RU 2191597):
A method of treatment of tuberculosis of peripheral lymph nodes / 2190970
The invention relates to medicine, to tuberculosis, to methods of treatment of tuberculosis of peripheral lymph nodes
A means to reduce the toxicity of chemically synthesized anti-tb drugs / 2190417
The invention relates to medicine and veterinary
A method of treatment of tuberculosis of the respiratory organs with severe exudative reaction in children / 2189234
The invention relates to medicine, to Institute, to methods of treatment of tuberculosis of the respiratory organs with severe exudative reaction in children
The method of treatment of pulmonary tuberculosis / 2188644
The invention relates to medicine
The way knee arthroplasty in patients undergoing tb drives / 2188588
The invention relates to medicine, Orthopaedics and traumatology, can be used in the prosthetic knee joint in patients undergoing TB drives
 Composition for treatment of pulmonary infections / 2185818
The invention relates to medicine and pharmacology, and relates to a composition for the treatment of pulmonary infections
 Tuberculostatic agent / 2185170
The invention relates to medicine, in particular tuberculosis and concerns chemotherapeutically antibacterial drugs for treatment of tuberculosis
 Composition for treatment of tuberculosis / 2185168
The invention relates to medicine and can be used in the treatment of tuberculosis
 For the treatment of tuberculosis with low complications fibrocycstic / 2185166
The invention relates to medicine, in particular to the treatment for tuberculosis with low fibrocycstic complications, which represents a conjugate isoniazid-dextran with molecular weight of 65-75 KD, of the formula:
 < / BR>where R1-N - glucose balance or polyglucosides the balance indicated on the drawing type; R2- the rest of isoniazid formula  < / BR>or hydroxyl group  Tablet antimicrobial action / 2185165
The invention relates to medicine, namely to the pharmaceutical industry, and can be used for the treatment of diseases that have arisen as a result of tuberculosis and chlamydia infection
 Polynucleotide tb vaccine / 2186109
 The method of increasing the resistance of experimental animals to xenobiotics / 2178712
The invention relates to experimental medicine
 Method for the diagnosis of leprosy / 2171689
The invention relates to medicine, namely to leprology, and can be used for the diagnosis of leprosy
 A method of obtaining a vaccine bcg-m for sparing primary immunization / 2170588
The invention relates to medicine, relates to a method of receiving the vaccine BCG-M for sparing primary immunization
 A method of obtaining a vaccine bcg "imuran" for immunotherapy of bladder cancer / 2170103
The invention relates to medical Microbiology
The method of differentiation of allergic reactions to ppd - tuberculin for mammals with allergen from rhodococcus / 2164804
The invention relates to veterinary medicine, in particular for the diagnosis of infectious diseases of cattle
 The method of indication of tubercle bacilli in the air / 2162709
The invention relates to the field of medicine
 The method of obtaining tuberculous toxoid / 2161984
The invention relates to biotechnology, in particular, to a method of obtaining tuberculous toxoid for specific prevention of tuberculosis
 The isolation and purification of a component of the microbial cell membrane lipid or sugar nature / 2155230
 Vaccine against tuberculosis / 2153354
The invention relates to medicine, namely to a vaccine against tuberculosis that is used for the prevention of tuberculosis
 Vaccine composition for prophylaxis and treatment of tuberculosis infection and genetic constructions for preparing acting components of this composition / 2262351
Invention proposes a vaccine composition used in prophylaxis and treatment of tuberculosis infection. The composition comprises a mixture of fused recombinant protein ESAT-HSP70 from Mycobacterium tuberculosis, protein HSP65 from M. tuberculosis and an inert vehicle. Also, the proposed composition can comprise timogen additionally. Also, invention proposes recombinant plasmid DNA pE HSP70 and pQE HSP65 encoding corresponding proteins. The proposed vaccine composition enhances effectiveness in treatment and prophylaxis of tuberculosis infection. Genetic constructions provide carrying out the stable expression of indicated proteins and to enhance purity the end preparing proteins. Invention can be used in treatment and prophylaxis of tuberculosis.
|
(57) Abstract: The invention relates to veterinary medicine. The method includes triple -, 6-, 8-, 18-month age - immunization of calves with BCG vaccine by intradermal injection of the drug at a dose of 2 mg in 0.2 ml of the solvent in the region of the middle third of the blade. Allergic diagnosis is carried out before the third vaccination. Injection of BCG carry out a syringe with needle, shortened to 2-3 mm using the method provided 70-100% protection of animals against tuberculosis in low labor consumption for preventive measures. 2 C.p. f-crystals, 6 PL. The invention relates to veterinary medicine and can be used in reindeer antler for the prevention of tuberculosis. The known method of prevention of tuberculosis of cattle with BCG vaccine. Calves aged 10-20 days subjected to immunization dose of 1 mg vaccine 0.3 mg solvent, intradermally on the right side of the neck at a distance of 8-10 cm from the front edge of the blade by means of a syringe and needle for intradermal injections (See. "Guidance on the use of BCG vaccine for tuberculosis in cattle" from February 26, 1990 - prototype). However, using the above method prnh in connection with biological characteristics and specific management system industry. So, because of the underdeveloped subcutaneous tissue volume of vaccine 0.3 ml cannot be used on purpose, because part of the vaccine when introduced subcutaneously flows from the place of introduction. For the same reason, when using a standard needle for intradermal due to their considerable length (8-15mm) and the low thickness of the skin fold intradermal injection of the drug is not guaranteed. Further, for drug injection in the neck region marlet to be secured, because it is a behavioral reaction in which maral-young trying to hide his head under standing next to it, and mane with hair growing on his neck, was difficult wittrig to the skin. Fixation is a high injury rate. In addition, the immunization in the first month of life marlet is almost impossible, because this requires them temporary isolation from their mothers, and any padding of youngsters in this age (given the half-civilized way of living) is also fraught with high injury and considerable effort. Under the current system of conducting industry-young is with mothers during the first 6 months and padding calves earlier impossible because of the biological characteristics of the animals. It is necessary to develop ways Profil result when immunization and low labor costs. This technical result is achieved in that in the method of TB prevention, including immunization of young animals by intradermal injection of BCG vaccine by syringe and needle for intradermal injection with subsequent allergic diagnosis of tuberculosis, immunization spend three times in 6-, 8-, 18-months of age at a dose of 2 mg vaccine in 0.2 ml of the solvent in the region of the middle third of the blade, and allergic diagnosis is carried out before the third vaccination with the delivery reacting to the slaughter. When this injection is carried syringe with needle, shortened to 2-3 mm In the conditions studied the effectiveness of different doses of BCG vaccine on maylath after padding from mothers at the age of 6 months, intradermally in the neck area. Test dose: 1 mg of BCG in 0.2 ml of solvent, 2 mg of BCG in 0.2 ml, 3 mg / 0.2 ml, 4 mg in 0.2 ml For the experiment was selected 5 groups of youngsters. The control group did not immunotherapies. The results of the immunological efficacy of different doses of BCG vaccine on maylath are given in table. 1. The main criterion for assessing the strength of immunity is the resistance of vaccinated animals to direct artificial infection with titles in healthy animals is now. Of the four tested variants dose of BCG vaccine was optimal 2 mg of dry matter, after immunization with 80% of vaccinated animals were not infected with the causative agent of tuberculosis (infection was carried out alimentary 2 mg bacterial mass per 1 kg of body weight of the animal). Indirect parameter estimation immunity against M. tuberculosis is a hypersensitivity of the delayed type (post-vaccination Allergy intradermal injection of tuberculin). Three herds of animals was studied post-vaccination Allergy depending on the dose of BCG vaccine. The results are shown in table. 2. The number of animals reacting to tuberculin, was studied in 60 days, because of post-vaccination Allergy is temporary in nature and manifests itself in 30-60 days, persisting over a period of 8-10 months, disappearing by the end of the year. According to the materials of experience we can conclude that the introduction of BCG vaccine at a dose of 1 mg compared to 2 mg marked not only fewer marlet, reacting to tuberculin, but intradermal vaccine-related reaction to the injection of tuberculin was less intense (4,81,3 mm compared to 45,51,2 mm). Thus, even with a twofold increased dose of vacci>The study of the dynamics of allergic reactions after vaccination has established its increase to 2 months, and 3 months was reduced to 4 month again increase. Almost a similar trend was observed in lymphoid organs. Therefore, revaccination marlet 2 months (i.e. 8-months of age) on the background of reducing hypersensitivity of the delayed type stimulates immunological processes in the body marlet by supplemental living Mycobacterium tuberculosis strain. BCG. This period is well consistent with the management system of the industry. So, if the space at the end of November, usually in December, 6 months of age and subsequent immunization needed a break in 1.5-2 months due to weak taming animals. Otherwise, there is a significant injury. Later, revaccination is impossible because in April of animals produced in parks. The effectiveness of revaccination after 2 months on the background of the optimal dose (0.2 ml) with regard to the introduction of vaccines (neck, shoulder) is shown in table. 3. From table. 3 shows that immunization of deer with BCG vaccine at a dose of 2 mg of dry matter in 0.2 ml of the solvent followed by reimmunization similar dose after 2 months predohranitelno with this, in the experiment studied the effect of the introduction of the vaccine in the formation of immunity. If the introduction of the vaccine in the neck of the animals were fixed in pancharatnam machine, and the hair at the injection was vestigal scissors, with the introduction of vaccines in the region of the shoulder blades of animals not recorded, placing them in the corner of one of the sections prestance corridor. They stood quietly, hiding their heads to each other, and hair due to its structure in this area was removed by visia hand. From these experiences, it is important that the vaccine does not influence the time, the intensity of vaccine-related allergic reactions and level of education of the immune system, however, the time spent on immunization one animal is reduced by 3-4 times. Production tests (table. 4) show that the above scheme and dose of BCG vaccine, provide immune rebuild an average of 97.9% of vaccinated animals. Production tests also showed that the introduction of the vaccine in the neck with fixing marlet in pancharatnam machine immunization 100 animals spent 2.5 hours, with the introduction of vaccines in the region of the scapula animals, grouped in sections predstanicne the ins skin marlet (subcutaneous tissue from deer underdeveloped), as shown by the production work, pierce the skin. In order to secure intradermal needles need to be shortened to 2-3 mm The level of immune protection marlet, vaccinated and tested dose and scheme of vaccination was determined not only by artificial infection, but in the conditions of natural infection in the joint content of the inoculated animals (experimental group) with naturally TB patients by deer (PL. 5), which was 83,3% for the group of healthy but not vaccinated animals (control group). A year after the first immunization of deer (i.e., at 28 months of age vaccine BCG vaccinated animals in 97-98% do not respond to intradermal injection of tuberculin. Reacting admit patients and subjected to slaughter, other revaccinated BCG vaccine at a dose of 2 mg in 0.2 ml of solvent. The method is as follows. In November - December marlet taken from mothers (6-month age), subjected to immunization with BCG vaccine by intradermal its introduction into the region of the middle third of the blade 2 mg dose of vaccine in 0.2 ml of solvent. This maral-young is not fixed, as it is enough to group them in one of the sections prestance corridor the temporary access. Immunization is performed by a needle for intradermal injections, shortened to 2-3 mm, which excluded the puncture of the skin and provide the necessary speed of operation. Revaccination in 8 - and 18-months (February-March) is similar. Before the third vaccination is carried out allergic diagnosis of a tuberculin (intradermally). Reacting recognize the sick and isolated. The results of the production test-proven doses and schemes immunization of marals are given in table.6. As can be seen from the above data, the claimed method for the prevention of tuberculosis of deer provides 97-100% protection of animals against tuberculosis in conditions of households with unfavorable epizootic situation. The test method in the red deer farms in the Altai region confirmed its high epidemic efficiency at low labor costs. 1. Method of prevention of tuberculosis of deer, including immunization of young animals by intradermal injection of BCG vaccine by syringe and needle for intradermal injection with subsequent allergic to TB diagnostics and slaughter reacting animals, characterized in that the immunization is carried out three times - in 6-, 8-, 18-month old in actinaria. 2. The method according to p. 1, characterized in that the intradermal injection is carried syringe with needle, shortened to 2-3 mm 3. The method according to p. 1, characterized in that the vaccine is injected into the middle third of the blade.
|